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Treatment and Prevention of 




Chikungunya fever is a vector borne tropical disease that was first described in 
an outbreak in Tanzania. The disease is caused by Chikungunya virus (CHIKV), an 
alpha virus belonging to the family Togaviridae and which is transmitted from one 
person to another via the bite of mosquitoes. Active disease is characterized by high 
grade fever, pain and joint symptoms. Although debilitating at times, the disease 
seldom progresses to result in a serious outcome like death. There are no specific 
treatments for Chikungunya virus at the moment. Clinical case management is 
highly dependent on providing palliative care which in turn is expected to alleviate 
symptoms and accelerate recovery from the infection. An important element in the 
control of outbreaks of CHIKV infection is prevention. Preventive strategies involve 
initiatives like vector control, immunizations and extra care to patients with the 
infection. There have been several tens of researches focusing on the introduction 
of newer drugs and vaccines against Chikungunya. That being said, so far, no single 
agent has completed the entire drug or vaccine development process. Chikungunya 
fever is a neglected tropical disease. Although it has no specific treatment till 
date, the number of vaccine and drug candidates under study provides promising 
insights on the prospects on chikungunya treatment.
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1. Introduction
Chikungunya fever was first described in Tanzania in the year 1952 during 
an outbreak in the southern part of the country. The disease is a vector borne 
infection transmitted by mosquitoes carrying the causative agent, Chikungunya 
virus (CHIKV), an RNA virus of the genus alphavirus and family Togaviridae [1]. 
CHIKV is transmitted to humans by bites of several species of mosquitoes, the two 
main species of mosquitoes transmitting the disease being Aedes aegypti and Aedes 
albopictus [2]. Major symptoms of the infection include fever (sudden high grade 
39–40°C), muscle and joint pain, swelling (joints), headache, nausea and other 
minor skin reactions [3]. Deaths from severe infections are not common and if any, 
the deaths are usually linked to other underlying medical conditions. Persons suffer-
ing an active infection may develop debilitating joint pain that gives them a distinct 
curved or bent posture and this is from which the disease’s name ‘Chikungunya’ was 
derived, which in the Makonde dialect means ‘to be contorted or bent’.
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Although Chikungunya fever occurs throughout the world, it is specifically 
common in the African continent. The disease is similar to many other febrile viral 
illnesses in terms of the clinical presentation of infected patients, thus; it can be 
misdiagnosed in areas where there are inadequacies of laboratory setups and testing 
procedures [4]. Even when it was first described as a disease in Tanzania, it was 
clinically indistinguishable from dengue fever [3]. For this reason, there are inac-
curacies in the numbers of infections of Chikungunya reported from various setups 
and in many instances, it is almost impossible to come up with a reliable estimate of 
the prevalence of the infection.
Currently, there are no commercially available vaccines or any specific drugs 
to cure Chikungunya fever and existing treatments generally focus on relieving 
symptoms. That being said, there have been immense research throughout the years 
in pursuit of specific drug candidates and vaccines to target the causative agent, but 
yet; no single entity was made available to the world. The most effective interven-
tion the world has been working on is to improve infection prevention strategies 
targeting activities ranging from vector control to prevention of mosquito bites and 
acquiring the infection.
This chapter provides brief highlights on the treatment approaches so far used, 
preventive strategies employed and promising prospective drug and vaccine candi-
dates whose development have been underway in the past few years.
2. Management of Chikungunya fever
Management of any infectious disease generally requires meticulous examina-
tion and a differential diagnosis in order to ascertain what is being dealt with in the 
first place. Before starting to treat Chikungunya fever, it is of utmost importance to 
rule out other viral infections, like Zika virus and Dengue fever, that have similar 
clinical presentation. Although in its severe form Chikungunya is a debilitating 
illness, like all other viral illnesses, the viral load of CHIKV is lowered by the body’s 
immune response, thus; the symptoms are self-limiting and patients usually fully 
recover.
There are generally two approaches into the treatment of any disease condition, 
namely the specific treatment that focuses on the cause of the disease and another 
is a non-specific intervention intended to alleviate symptoms of the disease. Today, 
there is no specific antiviral drug or vaccine intended for use against the CHIKV 
and for this reason, managing Chikungunya fever clinically is palliative, meaning 
it only focuses on relieving the symptoms [5]. There are various pharmacologic and 
non-pharmacologic approaches into doing this, the main of which are explored in 
the next section.
2.1 Symptomatic treatments
Symptomatic interventions generally work to alleviate the symptoms that may 
result from a disease condition without necessarily having to deal with the underly-
ing cause of the disease itself. In case of Chikungunya, a number of pharmacologic 
and non-pharmacologic approaches may be used to alleviate symptoms of the 
febrile illness.
2.1.1 Non-pharmacologic palliative care
Non-pharmacologic interventions do not employ the use of active chemical 
entities that modify or make use of a specific biochemical and/or physiological 
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processes to bring about the required change and thereby alleviate a symptom. Such 
interventions include life style elements like dietary modifications, fluid intake 
and bed rest. A common symptom in patients experiencing active Chikungunya 
infection is generalized body weakness and lethargy, thus; adequate nourishment 
and rest is very important to boost the patient’s immune response. Consumption of 
citrus fruits and the use of multivitamin supplements may also be recommended in 
some cases where there is loss of appetite. Taking plenty of fluids on the other hand 
helps the patient to stay rehydrated thereby maintaining stamina and metabolic 
stability. All these interventions play a vital role in optimizing the immune attack 
the body launches against the virus and thus not only alleviate the symptoms, but 
also accelerate the whole recovery process.
2.1.2 Pharmacologic palliative care
Pharmacologic interventions employ the use of specific active pharmaceuti-
cal entities which make use of specific bodily biochemical and/or physiological 
pathways to bring about a specific effect and thereby alleviate a symptom. The most 
common symptoms namely fever and joint pain can be alleviated with the use of 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). It is a fact that all NSAIDs have 
anti-pyretic (body temperature lowering) and analgesic (pain relieving) properties. 
Despite this fact, paracetamol or acetaminophen is more commonly used to manage 
fever and mild pain while drugs belonging to the same therapeutic class like ibu-
profen, diclofenac and naproxen are used to alleviate pain to maintain a favorable 
risk–benefit balance when using those medicines. Although Aspirin belongs to the 
NSAIDs, its use for analgesia and as an anti-pyretic agent is not recommended. This 
is in particular because of its blood thinning properties, giving the drug an unfavor-
able risk–benefit balance when used for these specific indications.
There are a number of studies debating over the use of chloroquine to treat 
the arthritis like symptoms of Chikungunya fever. Even if there is evidence that 
chloroquine is effective in managing various rheumatic joint diseases, its use for the 
management of Chikungunya fever related joint symptoms remains questionable. 
Disease-modifying anti-rheumatic drugs are also claimed to be effective in treat-
ing Chikungunya virus induced symptoms of chronic joint diseases that resemble 
rheumatoid arthritis in their presentation. The literature also presents other 
medicines like eupatorium perf, influenzinum, rhus-tox, pyroginum and cedron 
that are primarily utilized in south east Asia and are believed to play curative and 
 preventive roles.
Interventions to alleviate symptoms of Chikungunya, whether non-pharmaco-
logically or pharmacologically, are believed to be effective in improving prognosis 
and overall accelerating full recovery form the illness. A careful consideration 
should however be made when selecting an appropriate treatment, particularly 
a pharmacological palliative intervention, for the patient so that the risk benefit 
balance of using the treatment remains favorable.
2.2 Specific treatments
In principle, a specific treatment is supposed to completely cure a disease. This 
would mean that the treatment will precisely target the pathophysiological root 
cause of the disease in the case of non-infectious disease and the invading causative 
agent in the case of an infectious disease.
Till date, there is no single antiviral entity proven to be specifically effective 
against the CHIKV. There have however been several antiviral candidates under 
study to target the virus. With regard to active and passive immunizations against 
Chikungunya
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the virus, no vaccine is commercially available for use in humans today. There are 
however several vaccine strategies under study and some vaccine candidates have 
now reached to advanced stages in the clinical development process. These candi-
dates are however still long way from the approval step and longer way from being 
available in markets for consumption.
The management of Chikungunya fever is primarily palliative. Until the 
time when specific curative alternatives are made available, it is recommended 
that health practitioners make wise use of the available treatment options. 
Moreover, there are various recommended treatment guidelines specific to 
Chikungunya fever that provide clear steps on how effectively one can manage 
the  infection [3].
Table 1 summarizes the various approaches used today and the likely to be 
future treatment options in the management of CHIKV.
3. Preventive measures
The prevention of disease acquirement and transmission is key to halt the 
spread of any infectious disease. In case of Chikungunya virus infection, preven-
tion becomes vital to control spread especially that there are no specific treatments 
against the disease. There may be several preventive strategies to control the spread 
of Chikungunya fever. For the purpose of clarity, this section summarizes them into 
three major approaches namely vector control measures, immunizations and care 
for the already diseased persons.
3.1 Vector control and avoiding mosquito bites
Chikungunya is an arthropod borne viral infection. CHIKV is transmitted to 
humans by bites of several species of mosquitoes [2, 3]. The two main species of 
mosquitoes transmitting the disease are Aedes aegypti and Aedes albopictus. Aedes 
aegypti is commonly responsible for transmission in urban areas whereas Aedes 
albopictus has been the main vector in rural areas. These mosquitoes can be easily 
distinguishable from others by the presence of white markings on their limbs and 
a marking in the form of a lyre on the upper surface of the thorax. Recognizing 





Real-time: Dietary modification, rehydration and bed rest 
all play key role in boosting the immune responses against the 
virus and thus facilitating full recovery.
Pharmacologic 
treatment
Real-time: The use of NSAIDs such as paracetamol or 




Antiviral drugs Prospective: Specific antiviral drugs that target CHIKV by 
interfering with the various vital steps in the viral replication 




Prospective: The use of specific preformed antibodies that 
directly target the whole virus or viral coat molecules there by 
clearing viral particles.
Table 1. 
Real-time and prospective approaches for the management of chikungunya fever.
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the mosquito itself is very important as it gives an insight into the possibility of the 
existence of an outbreak in a specific area.
The control and termination of breeding of the vector is key to the prevention of 
the transmission of any vector borne infection. In the control of CHIKV outbreaks, 
vector control through the use of larvicides and adulticides, the removal of larval 
habitats, limiting human-vector contact and public education is critical [6]. The 
measures that should be taken in vector control are similar to those used in the 
control of transmission of malaria. The common measures that should be taken 
include:
• Emptying and scrubbing, turning over, burying, covering, or throwing out 
items that hold water. Since mosquitoes need water to lay eggs, it is very 
important to cover or dry swampy spots in the surrounding of the outdoors of 
living places.
• Using insecticides and repellents to kill and/or keep away mosquitoes from 
indoors and thereby avoiding bites.
Another important measure that should be taken to control the spread of 
CHIKV is to avoid mosquito bites. There are a few things that can be done to 
avoid bites:
• Recognizing the mosquito based on its physical appearance (white markings) 
and being aware that unlike the mosquitoes that spread malaria which are usu-
ally active and bite during the night time, the Aedes species are active and bite 
during both the day and the night times.
• Sleeping under a mosquito net especially in areas where mosquito breeding 
rates are very high. Such places may include high humidity and swampy areas.
• Applying mosquito repellents. There are a wide variety of products that 
contain mosquito repellents and are available in different formulations such as 
lotions and creams.
Since mosquitoes have a major role in the spread of CHIKV, targeting them is 
key to halt the transmission cycle. Vector control comprises a set of activities, not 
limited to the above described, intended to minimize transmission of CHIKV and 
thereby the occurrence of active Chikungunya infections.
3.2 Immunization
Active immunization against specific foreign entities entering the human body 
has been one of the most effective strategies in the prevention of communicable dis-
eases. Like other infectious diseases, CHIKV has been a subject of interest for many 
vaccine developers. There is however no vaccine that have been made commercially 
available for preventive immunizations against the disease.
Recent studies list a number of candidates that are under development [7, 8]. Of 
the candidates, there is a single vaccine that have made progress to phase three clini-
cal trials, which seems to be the most progressing out of the rest of the candidates 
[9]. That being said, according to what is published in the scientific literature thus 
far, making a vaccine available for human use does not seem to be something that 
one should expect in the very near future.
Chikungunya
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3.3 Special care for the diseased
Just as the mosquito plays a major role in the transmission cycle of CHIKV, 
so does the infected patient. The already diseased patient is actually incubating 
the causative agent. It is, for this very reason, important that infected persons be 
protected from further mosquito exposure during the first few days of the illness 
when the viral load is high, so they can not contribute to the transmission cycle. 
Preventing further mosquito bites can be achieved through the same measures 
listed under the vector control and bite prevention strategies.
The main preventive strategies that could be adopted to limit outbreaks of 
CHIKV are briefly described in Table 2.
The world has not gone too far in developing a specific cure for Chikungunya 
fever. Apart from the common notion that ‘prevention is better than cure’, in the 
case of Chikungunya, prevention becomes of a particular interest because, until 
today, there are no specific antiviral therapies or vaccines (whether active or passive 
immunizations) that are proven to be safe and effective. It is hence important that 
centers of disease control and prevention pay due attention in this regard and take 
proactive measures to prevent or at least limit outbreaks.
4. Prospects on the introduction of new drugs and vaccines
As is the case with many other bacterial, viral or fungal infectious diseases, 
Chikungunya fever has been a subject of interest for many researchers in pursuit of 
new drug therapies and vaccines. Despite the fact that much effort has been done so 
far, there is still no antiviral proven to be specifically effective against CHIKV while 
being safe for use in humans [10]. Moreover, no vaccine has been made available 
S.No. Strategy Category Description
1. Vector Control Minimizing 
mosquito breeding
Controlling mosquito habitats (water holes, 
swamps and dump areas) and use of insecticides, 




Sleeping under mosquito nets, avoiding shorts 
and short sleeved wears during both day and 
night times (to minimize open exposure of the 
skin surface) and the application of mosquito 
repellents.
2. Immunizations Active 
immunization
Vaccinating healthy individuals to develop 
active immunity against the infection. With no 
consideration given to their safety profile, only a 
few vaccine candidates have shown demonstrable 
efficacy in eliciting adequate immune responses 
against CHIKV.
3. Patient care Host control Infected patients are sources of the virus. 
Protecting the infected patient from further 
mosquito bites reduces the chances of 
transmission.
4. Health education Public awareness Educating the public on the preventive strategies 
and how to seek medical care if they suspect they 
are infected. Moreover, describing the mosquito, 
its physical features and behavior.
Table 2. 
Strategies for the prevention of spread of CHIKV.
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for use by humans. It is however worth reflecting the trends on the development 
of newer drugs and vaccines for chikungunya and to explore the various strategies 
employed in their development. This particular section summarizes the prospects in 
drug and vaccine development for Chikungunya fever.
4.1 Development of antiviral agents and the strategies employed
An antiviral agent is an entity that specifically targets a virus resulting in disrup-
tion of viral particles, prevention of replication and/or acceleration of viral clear-
ance through immunological mechanisms.
There have been a number of trails conducted in pursuit of a safe and effective 
antiviral agents working specifically against the CHIKV. The candidates being tested 
in the different trials are variable and target CHIKV through variable ways. Some of 
the agents under study are small CHIKV inhibitor molecules and others are natural 
inhibitors of viral replication [8, 11]. There are also repurposed drugs, monoclo-
nal antibodies, gene silencers and viral particles that work more or less through 
immune modulation. In the last decade, more than 30 antiviral agents that are 
thought to be effective against CHIKV were patented [8]. There are several antiviral 
agents studied so far, the description of some of which is briefly explored below.
4.1.1 Inhibitors of CHIKV
The CHIKV inhibitors is a category comprising a large array of compounds 
including small inhibitor molecules, inhibitors from natural sources, repurposed 
drugs and so on. This drugs utilize various biochemical pathways to inhibit the 
replication of CHIKV. There are several tens of agents being studied under this 
category, the majority of which are in the early stages of drug development. For 
instance, ribavirin, arbidol, chloroquine, Epigallocatechin Gallate (EGCG) and 
ribostamycin sulfate are some of the many drugs that fall under this category [8].
CHIKV inhibitors exert their antiviral actions through a number of mechanisms. 
Majority of these agents are viral replication inhibitors. They interfere in various 
stages of viral replication such as gene transcription, assembly of viral particles into 
virions and budding of virions out from the host cell. Other agents are thought to 
contribute to viral clearance by the immune responses. None of these agents has 
fully gone through the entire drug development process and thus non are made 
available in the market.
4.1.2 Monoclonal antibodies
The use of monoclonal antibodies in the treatment of various infectious and 
non-infectious diseases has been a very helpful strategy in the past few decades. 
Monoclonal antibodies are more or less a simple model of passive immunizations 
where preformed antibodies work to directly infiltrate viral particles.
There are many trials made on agents being developed as monoclonal antibodies 
to work against CHIKV. The introduction of antibodies that are effective against 
proteins of CHIKV could be a potential approach leading to vaccine development 
as a treatment. These agents that make use of the immune system of the host 
stimulates various immune modulators such as type I interferons and antibodies 
during the initial stages of an infection with CHIKV [12], Immunoglobulin M (IgM) 
antibodies during an acute phase [13] and Immunoglobulin G (IgG) antibodies for 
infections persisting longer [14]. Neutralizing antibodies can be of help to prevent 
budding of CHIKV from infected host cells and thus interfere with the viral release 
from the host stage of the replication process [15].
Chikungunya
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In this prospect, the use of Monoclonal antibodies seems to be a very prom-
ising approach towards the introduction of new antiviral treatments against 
Chikungunya in the not too far future.
4.1.3 Vaccines
Although generally and in principle vaccines have a bigger role in the prevention 
of acquiring active diseases, their use as therapeutic agents have become a com-
monly employed strategy especially in the essence of passive immunization where 
recipients are given readily made antibodies that directly work to neutralize the 
causative agent. The previously discussed principle about monoclonal antibodies 
was more or less preceded by such ideas about neutralization.
In the area of vaccine development against Chikungunya, various efforts have 
been made in the last decade to develop effective vaccines for the treatment of 
CHIKV infections. A number of live-attenuated virus vaccines, inactivated virus 
vaccine, recombinant viral component vaccines, DNA and mRNA-based vaccines, 
synthetic vaccines, subunit formulations of CHIKV and others have been developed 
[16]. Further details on vaccine development will be discussed in the section that 
follows.
4.2 Development of vaccines and the strategies employed
The introduction of vaccinations against CHIKV has been a subject of interest 
ever since the disease was first described decades back. Immunizations in general 
can be active and/or passive. Active immunization refers to the exposure of the body 
to a foreign entity resulting in the initiation of body’s immune responses weather 
cell mediated or antibody mediated. The development of immunological memory 
will then result in prompt immune responses in subsequent invasions by the foreign 
agent to which memory was developed. On the other hand, passive immunization 
refers to the transfer, into the body, of readily made antibodies that may directly act 
upon the foreign entity in the body. In this case, the neutralization of the invading 
agent is much faster as there is no time lapse between sensitization and secretion 
of antibodies. In the development of vaccines against chikungunya, both types of 
vaccine agents have been under study [17].
4.2.1 Passive immunization
Passive immunization against the CHIKV refers to the introduction of 
preformed antibodies that directly act upon the causative virus. This is briefly 
discussed in the previous section where monoclonal antibodies are presented as 
therapeutic antiviral agents. Human protection from CHIKV infection is primar-
ily mediated by humoral memory host response and the presence of neutralizing 
antibodies targeting the virus’s outer surfaces of envelope glycoproteins [18]. There 
are studies that support the efficacy of monoclonal antibodies as post exposure 
therapy against CHIKV infections. Passive immunization therefore seems to be 
another prospect for the introduction of effective interventions against chikungu-
nya in the future.
4.2.2 Active immunization
Active immunization employs the introduction of an antigen into the body to 
elicit an immune response and memory against the foreign agent. It is considered to 
be the most cost-effective preventive health intervention so far. The development of 
9
Treatment and Prevention of Chikungunya Fever: Current Status and Prospective
DOI: http://dx.doi.org/10.5772/intechopen.98523
a CHIKV vaccine seems to be feasible because the virus has a relatively low antigen 
diversity compared to other similar viruses [17]. This would also imply that changes 
in vaccine effectiveness profiles, assuming an effective vaccine is made avail-
able, are less likely to occur due to the less rapid rate of mutations observed with 
the virus.
Until 2016, three experimental vaccines have advanced to the stage of human 
testing. Two candidates namely, the VRC-CHKV133 and the MVCHIK127 vac-
cines finished phase I, in 2014 and 2015 respectively. The third candidate (CHIKV/
IRES115 vaccine) yielded promising efficacy and safety results in mice and 
macaques and plans are in place for a phase I trial. It is worth of note that there is 
one candidate that have advanced to phase three trials in 2020 [9]. This prospect 
gave hope to many disease control program managers.
Table 3 provides a summary list of the most advancing drug and vaccine devel-
opment approaches for CHIKV.
5. Chapter summary
Chikungunya fever is a vector borne infection caused by Chikungunya virus. 
The virus is transmitted by the bites of two main mosquito species namely, Aedes 
aegypti and Aedes albopictus. The disease is characterized by several symptoms the 
major of which are high grade fever, joint pain and joint inflammation. Severe infec-
tions are debilitating and may require the patient to be bedbound or may even result 
in death, though very rare, in cases where the patient has a compromised overall 
health status.
Currently, there are no specific anti-viral drugs against the Chikungunya virus 
and treatments are designed to alleviate symptoms. There are a number of pallia-
tive pharmacological and non-pharmacological treatment options which may offer 
symptomatic relief and accelerate recovery from the infection. The use of non-ste-
roidal anti-inflammatory agents to alleviate fever, pain and various joint symptoms 
associated with the disease has been a very effective management option. Some 




Inhibitors of CHIKV 
(simple molecules)
• A group of compounds that interfere with various steps in the 
viral replication cycle.
• More than 30 candidates under study.
• Example: ribavirin and arbidol.
Monoclonal 
antibodies
• Target specific immune modulators that neutralize virions.
• Example: monoclonal antibodies that stimulate immune 
response mediators such as type I interferons, IgM and IgG in 
various stages of the infection.
Vaccine Passive immunization • Preformed antibodies that directly act to clear virions.
• Fast onset of action (neutralization).
• Example: serum purified antibodies.
Active immunization • Antigen based antibodies that stimulate the immune system to 
develop memory against CHIKV.
• Example: vaccine candidates under development such as VRC-
CHKV133, MVCHIK127 and CHIKV/IRES115.
Table 3. 
CHIKV drug and vaccine development strategies.
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of more vitamins and minerals to boost the immune response to the infection have 
also been some of the recommended care approaches. The overall goal of palliative 
care is to reduce suffering and accelerate recovery.
Exploring the various preventive strategies adopted to minimize the transmis-
sion of Chikungunya virus is of utmost importance. The general notion of disease 
prevention is more pronounced when treatment options are limited or inexistent. 
The absence of specific treatment for Chikungunya therefore necessitates that due 
attention is given to prevention. Although several strategies may be employed to 
prevent viral transmission, vector control has been the one major approach to halt 
spread of the infection. Prevention of mosquito bites becomes as important to the 
already infected as it is for the uninfected person in terminating the transmission 
cycle. In another scene, despite the recognition that immunizations have for so long 
been the most cost effective preventive health interventions and the efforts made 
to discover some, no specific CHIKV vaccine has so far been made commercially 
available and thus the use of vaccines as preventive measures is yet to come.
As it is the case with many novel viral diseases, Chikungunya has for decades 
been a subject of interest to drug and vaccine development firms. The current status 
and prospective with regard to new drug and vaccine development and clinical 
trials for cures and immunizations against this viral disease seems to be promising. 
Many new trails on animal models are currently underway and a few drug and vac-
cine candidates made it to testing in humans. Several tens of antiviral agents have 
advanced to the late stages of drug development. These entities come in various 
forms ranging from simple molecules, agents from natural sources and macromol-
ecules such as monoclonal antibodies. On the other hand, a number of vaccines 
have also been under development and one candidate has so far advanced to phase 
three clinical trials, thus demonstrating acceptable safety and efficacy.
In light of the seriousness and debilitating nature of Chikungunya fever, the 
pursuit for newer treatment options and preventive strategies such as vaccinations 
should inevitably be encouraged. Neglected tropical diseases, as their name implies, 
have for long been ignored in many aspects in attempts to favor policies and resource 
allocations towards diseases that are deemed deserving priority based on their public 
health threat profile. Chikungunya fever is a neglected tropical disease, yet, the bulk 
of research carried out in this area is commendable and the trends demonstrate a 
possibility for the introduction of a novel treatment option in the near future.
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